MabCure Announces Agreement with the City University of New York Center for Advanced Technology to Validate and Evaluate Its Monoclonal Antibodies as Ovarian Cancer Diagnostic Reagents - MarketWatch

MabCure Announces Agreement with the City University of New York Center for Advanced Technology to Validate and Evaluate Its Monoclonal Antibodies as Ovarian Cancer Diagnostic Reagents - MarketWatch

Mabcure Study Results on a New Ovarian Cancer Diagnostic Blood Test Being Presented at the Annual Meeting of the SGO - financial news

MabCure, Inc. Files Provisional Patent in the U.S. for Ovarian Cancer Antibodies - press release/financial news

"In a blinded study of 54 blood samples, MabCure's MAbs correctly diagnosed 16 of the 17 ovarian cancers with a diagnostic sensitivity of 94 percent and 100 percent specificity. The samples were comprised of 17 patients with ovarian cancer, 5 patients with benign tumors of the ovaries, 24 healthy young females and 8 males.

"Beyond the value of our test to diagnose ovarian cancer in a highly accurate manner and with no false positives, the potential value of our proprietary MAbs is also in helping to identify tumor-specific antigens or cancer-specific targets for the ultimate treatment of ovarian cancer," said Gonenne."

MabCure, Inc. Announces Positive Results For New Ovarian Cancer Diagnostic Blood Test -- HASSELT, Belgium, July 27 - press release

"...MabCure will soon commence a follow-on study in collaboration with one of the foremost experts in women's cancers, Ignace Vergote, M.D., Head of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven, Belgium. The study will access a large number of previously collected clinical blood samples stored at the Bio-bank of the Catholic University Hospital, Leuven.

Following the conclusion of this study, MabCure plans to launch a multi-center prospective trial in Europe and in the U.S., as well as initiate commercialization of its diagnostic ovarian cancer MAbs in Europe through strategic partnerships and licensing. In parallel, MabCure plans to embark on the regulatory process for obtaining marketing approval in the U.S.

MabCure is currently evaluating the diagnostic potential of it MAbs in detecting ovarian cancer in high-risk patients in a clinical study in Thailand...."

news item: Mabcure Launches Clinical Trial to Diagnose Ovarian Cancer